3 Best ASX growth stocks to buy

Not every growth story needs loud headlines to make an impact. Some businesses simply keep executing, strengthening their market position and giving investors more reasons to pay attention.
That is exactly what these three companies are doing. From software and AI to healthcare technology, each one is carving out its own space in the ASX growth stocks universe with steady progress and strong business momentum.

TechnologyOne Limited (ASX: TNE) 

continues to stand out as one of the more interesting names among ASX growth stocks especially for investors looking at software businesses with strong visibility. 
The company recently upgraded its FY26 guidance and now expects profit growth of 18% to 20% along with ARR growth of 16% to 18%. 

Management has linked this confidence to strong customer pipeline momentum across Australia, New Zealand and the UK along with rising excitement around its SaaS+ and AI-driven offerings. What makes the story more compelling is that the company is not just talking about future opportunities but backing it with higher guidance and solid operating rhythm. 

Even though first half profit growth may appear softer due to upfront investment in AI showcase launches, management expects a much stronger second half. That kind of confidence usually catches investor attention.

Xero Limited (ASX: XRO) 

is steadily building a strong case for itself as a business that can benefit from both software adoption and the next wave of AI led productivity. 

In its February 2026 investor briefing the company highlighted how AI could expand its long-term addressable market significantly while also strengthening its position with small businesses. More than two million subscribers are already using Xero’s AI features, and the company is now pushing further into automation, decision making tools and business insights. 

Its integration with Melio is helping deepen its US payments opportunity and improve unit economics. Xero’s strength lies in its role as a trusted system of record for small businesses which gives it a real advantage when building AI led tools. 

For investors screening ASX growth stocks, this mix of scale, product depth and future monetisation opportunities makes Xero a name worth watching closely.

Pro Medicus Limited (ASX: PME) 

continues to show why it remains one of the highest-quality healthcare technology names on the market. The company delivered a strong first half FY26 result with revenue rising 28.4% to $124.8 million and underlying profit before tax increasing 29.7% to $90.7 million. 

It also remained debt-free and ended the period with $221.8 million in cash and financial assets. 
Pro Medicus signed seven new contracts during the half with a total minimum value above $280 million while also completing six cloud-based implementations. The company’s operating model remains highly scalable, and management continues to see strong momentum in its pipeline. 

Pro Medicus offers a mix of strong financial performance, global contract wins and business model that can scale without putting much pressure on costs.

 (Graphic Source: Company Reports)